Ocular Therapeutix
OCUL
148 hedge funds and large institutions have $1.13B invested in Ocular Therapeutix in 2024 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 60 increasing their positions, 23 reducing their positions, and 16 closing their positions.
242% more capital invested
Capital invested by funds: $330M → $1.13B (+$798M)
194% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 16
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
161% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 23
25% more funds holding
Funds holding: 118 → 148 (+30)
16.37% more ownership
Funds ownership: 67.17% → 83.54% (+16%)
79% less call options, than puts
Call options by funds: $2.95M | Put options by funds: $14.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$50.7M |
| 2 |
SR
Summer Road
West Palm Beach,
Florida
|
+$47.6M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$37.7M |
| 4 |
VA
VR Adviser
New York
|
+$35.4M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$24.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$16.5M |
| 2 |
Millennium Management
New York
|
-$4.3M |
| 3 |
SCM
Sio Capital Management
New York
|
-$4.18M |
| 4 |
BS
Banco Santander
Madrid,
Spain
|
-$2.36M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.64M |
OCUL Hedge Fund Activity: Q1 2024 in Review
148 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2024, worth a combined $1.13B — up 242% from $330M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new OCUL positions and 16 closed out — a net gain of 31 holders — while 60 added to existing stakes and 23 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $50.7M. The largest seller was Franklin Resources, cutting an estimated $16.5M.
- 148 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2024, up from 118 in Q4 2023.
- Funds reported $1.13B of Ocular Therapeutix stock for Q1 2024, up 242% quarter-over-quarter.
- 47 funds opened new Ocular Therapeutix positions in Q1 2024 and 16 closed out, a net change of +31 holders.
- The largest Ocular Therapeutix buyer in Q1 2024 was Avoro Capital Advisors, an estimated $50.7M added.
- The largest Ocular Therapeutix seller in Q1 2024 was Franklin Resources, an estimated $16.5M sold.
Based on aggregated 13F filings for Q1 2024.